Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Stronger Sell Today ALNY ranks #3339 as SELL CANDIDATE #3339 Weaker Sell

ALNY stock forecast Alnylam Pharmaceuticals

ALNY stock forecast

Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.

Read more

Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

Read more

Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change

Read more

Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.

Read more

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Read more

The highly volatile biotech stocks present a high-risk-high-reward proposition. Judicious stock picking is essential to ride the superlative rally in some of these stocks in the wake of make-or-break binary events. Here's a brief on a few small-cap biotech stocks Citigroup analyst Yigal Nochomovitz recommends as investment worthy and the rationale behind the thinking. The analyst assumed coverage of these stocks on May 24. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ): Buy rating, $30 price target (154 percent upside potential) Dicerna's lead candidate DCR-PHXC is in a pivotal Phase 2 study for primary hyperoxaluria, or PH, Types 1 and 2 – a severe, genetic liver disorder that results in the overproduction of oxalate, Nochomovitz said. Although Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) has a competing product in a Phase 3 trial, the approach of its treatment candidate makes it effective only for PH Type 1, while Dicerna's is amenable to treat all three subtypes of PH, he added. Dicerna's DCR-HBV being evaluated for hepatitis B virus infection represents a large upside opportunity, …

Read more

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ: PRQR ), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results for the first quarter ended March 31, 2019. "We made significant progress in 2019 thus far with the initiation of both the Phase 2/3 trial for sepofarsen and the proof of concept trial for QR-421a in Usher syndrome as we focus on our mission to become a fully-integrated company developing and commercializing RNA medicines for patients with inherited retinal diseases," said Daniel A. de Boer, CEO of ProQR. "We expect 2019 to be a transformative year for ProQR as we execute on these trials and advance three additional programs towards the clinic in our effort to bring more innovative medicines for inherited retinal diseases to patients." Corporate Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 In April 2019, the first patient was dosed in the Phase 2/3 ILLUMINATE trial in patients with sepofarsen in Leber's Congenital Amaurosis 10 (LCA10) with data expected around the end of 2020.

Read more

Additional drug approvals and launches are on the way.

Read more

Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.

Read more

Investors are starting to wonder if there's anything that can lift this stock higher.

Read more

ALNY earnings call for the period ending March 31, 2019.

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank